Clinical trialPhase 2Unknown
Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer
Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer: A Single-arm Phase II Clinical Trial
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 April 2018
- Expected end
- June 2020
- Enrollment
- 52 participants
- Sites
- 1
- Primary outcomes
- Objective response rate; Disease control rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 April 2018
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- BackgroundA modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tol… DOI 10.1177/1758834016676011↗
- BackgroundDose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreat… DOI 10.21037/jgo.2016.01.03↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗